Terns Pharmaceuticals Inc (STU:430)
€ 5.6 0.05 (0.9%) Market Cap: 470.26 Mil Enterprise Value: 113.82 Mil PE Ratio: 0 PB Ratio: 1.34 GF Score: 39/100

Terns Pharmaceuticals Inc at UBS BioPharma Conference Transcript

Nov 08, 2023 / 09:30PM GMT
Release Date Price: €4.53 (+2.72%)
Ellie Merle
UBS - Analyst

Hi. Good afternoon, everyone. I'm Ellie Merle, one of the biotech analysts here at UBS. Very happy to have Terns Pharmaceuticals here with us today. Joining us from Terns is Mark Vignola, Chief Financial Officer; and David Strauss, Vice President of Finance.

It seems Mark has had a lot of investor meetings and is literally losing his voice. So David will be on the hot seat for these questions. But thank you, guys, so much for joining us.

Mark Vignola
Terns Pharmaceuticals, Inc. - CFO

Thanks for having us.

David Strauss
Terns Pharmaceuticals, Inc. - VP of Finance

Thank you.

Ellie Merle
UBS - Analyst

Maybe before we dive into questions, can you just -- you have a bunch of programs ongoing. Can you give us a brief high-level overview of the company and your strategy and pipeline?

David Strauss
Terns Pharmaceuticals, Inc. - VP of Finance

Yeah, that'd be great to do that. So we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot